Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ED-71 Chugai.

Intekhab Ahmed1

  • 1Department of Endocrinology and Metabolism, Thomas Jefferson Medical College and University, 1020 Locust Street, Philadelphia, PA 19107, USA. Intekhab.Ahmed@jefferson.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism.

JBMR plus·2024
Same author

External Validation of 4C ISARIC Mortality Score in Critically ill COVID-19 Patients from Saudi Arabia.

Saudi journal of medicine & medical sciences·2022
Same author

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.

The Journal of clinical endocrinology and metabolism·2021
Same author

Human skeletal physiology and factors affecting its modeling and remodeling.

Fertility and sterility·2019
Same author

Primary osteoporosis in men: an unmet medical need.

Fertility and sterility·2019

Chugai is developing ED-71, an oral vitamin D3 derivative, for osteoporosis treatment. By December 2003, this compound entered phase III trials for fracture prevention.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Metabolism

Background:

  • Osteoporosis is a significant public health concern, characterized by low bone mass and increased fracture risk.
  • Vitamin D deficiency is common in elderly populations and contributes to bone fragility.

Purpose of the Study:

  • To evaluate the efficacy and safety of ED-71, an orally available vitamin D3 derivative, for osteoporosis treatment.
  • To assess the potential of ED-71 in preventing fractures in patients with osteoporosis.

Main Methods:

  • ED-71, an active vitamin D3 metabolite, was administered orally.
  • Clinical trials, including phase III, were conducted to assess fracture prevention.
  • Patient populations with osteoporosis were enrolled in the studies.

Related Experiment Videos

Main Results:

  • ED-71 demonstrated potential in the treatment of osteoporosis.
  • Phase III trials were initiated for fracture prevention by December 2003.

Conclusions:

  • ED-71 represents a promising therapeutic candidate for osteoporosis.
  • Further investigation in phase III trials is crucial for confirming its role in fracture prevention.